文献速递核素与放射性配体治疗肿瘤 PET/CT

剂量异质性对90Y-SIRT治疗肝细胞癌疗效与毒性的影响

Effects of dose heterogeneity on response and toxicity after 90Y-SIRT for HCC.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2026-07-14

本研究回顾性纳入45例肝细胞癌患者的68个病灶,分析90Y树脂微球SIRT后PET/CT剂量分布与mRECIST疗效及≥3级毒性的关系。结果显示空间剂量分布超越平均吸收剂量影响结局:低D50病灶中热区异质性与疗效相关,高D50病灶中冷区指标与疗效相关;非肿瘤肝平均剂量与急性毒性相关,剂量异质性与迟发毒性相关。

要点

  • 低D50病灶中热区异质性与更好疗效相关,高D50病灶中冷区指标与更好疗效相关。
  • 非肿瘤肝平均剂量与急性毒性相关,剂量异质性与迟发严重毒性相关。
  • D50在mRECIST各疗效类别间无显著差异,空间剂量分布提供额外信息。

核心结论

  • 空间剂量分布对90Y-SIRT结局的影响超越平均吸收剂量。
  • 肿瘤疗效与剂量水平依赖的模式相关:低剂量水平下热区驱动异质性与疗效相关,较高剂量水平下冷区指标更相关。
  • 毒性存在时间分离:非肿瘤肝平均剂量与急性损伤相关,空间剂量异质性与迟发严重毒性相关。

研究设计与样本

  • 回顾性研究,纳入45例肝细胞癌患者的68个病灶,均接受90Y树脂微球SIRT。
  • 剂量分布来自治疗后90Y PET/CT,采用DVH指标包括热区(D2、D10、Dmax)、冷区(D90、D98、Dmin)和覆盖参数(V100、V150、V200)。
  • 疗效采用mRECIST评估,≥3级毒性分为急性或迟发,病灶按中位吸收剂量分层(D50 < 128 Gy vs. ≥ 128 Gy)。

主要发现

  • 68个病灶中44%达到完全缓解。
  • D50在mRECIST各疗效类别间无显著差异。
  • 低D50病灶中,较高异质性与更好疗效相关,热区指标(D2、D10、Dmax)呈相似趋势。
  • 高D50病灶中,冷区指标(D90、D98)与更好疗效显著相关。
  • 非肿瘤肝平均剂量与急性毒性相关,剂量异质性与迟发毒性相关。

关键数值与推荐

  • 病灶按D50 < 128 Gy vs. ≥ 128 Gy分层。
  • 疗效评估采用mRECIST,毒性按≥3级分为急性或迟发。
  • DVH指标包括热区D2、D10、Dmax,冷区D90、D98、Dmin,覆盖参数V100、V150、V200。

临床怎么用

  • 90Y-SIRT计划与评估中除平均吸收剂量外,应关注空间剂量分布指标。
  • 低D50病灶可关注热区异质性,高D50病灶可关注冷区覆盖指标以预测疗效。
  • 非肿瘤肝平均剂量用于急性毒性预警,剂量异质性用于迟发严重毒性预警。
  • 支持进一步评估空间剂量学用于个体化SIRT规划。

局限性

  • 回顾性研究设计。
  • 样本量较小(45例患者、68个病灶)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Yttrium-90 (90Y) selective internal radiation therapy (SIRT) is an established treatment for hepatocellular carcinoma (HCC), yet dose-response relationships remain incompletely understood. We evaluated whether voxel-based dose heterogeneity is associated with tumour response and treatment-related toxicity. METHODS: This retrospective study included 45 HCC patients with 68 lesions treated with 90Y resin SIRT. Dose distributions were derived from post-therapy 90Y PET/CT. DVH-based metrics included hot-spot (D2, D10, Dmax), cold-spot (D90, D98, Dmin), and coverage parameters (V100, V150, V200). Tumour response was assessed using mRECIST. Grade ≥ 3 toxicity was classified as acute or latent. Lesions were stratified by median absorbed dose (D50 < 128 Gy vs. ≥ 128 Gy). RESULTS: Of 68 lesions, 44% achieved complete response. D50 did not differ significantly across mRECIST response categories. In low-D50 lesions, higher heterogeneity was associated with improved response. Hot-spot metrics (D2, D10, Dmax) showed similar trends. In high-D50 lesions, cold-spot metrics (D90, D98) were significantly associated with better response. Mean non-tumoral liver dose was associated with acute toxicity, while dose heterogeneity was associated with latent toxicity. CONCLUSION: Spatial dose distribution influences outcomes beyond mean absorbed dose. Tumour response was related to a dose level dependent pattern, with hot-spot-driven heterogeneity associated with response at lower dose levels and cold-spot metrics more relevant at higher dose levels. In addition, a temporal dissociation in toxicity was identified, with mean non-tumoral liver dose associated with acute injury and spatial dose heterogeneity associated with latent severe toxicity, supporting further evaluation of spatial dosimetry for individualized SIRT planning.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Xi H, Zheng X, Glaudemans AWJM, et al. Effects of dose heterogeneity on response and toxicity after 90Y-SIRT for HCC. Eur J Nucl Med Mol Imaging. 2026. PMID: 42446581. doi:10.1007/s00259-026-08064-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。